CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.320
0.00 (0.00%)
At close: Dec 5, 2025
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
403.93M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Zomedica | 29.45M |
CytoDyn News
- 5 days ago - CytoDyn Announces Resolution of Class Action Lawsuit - GlobeNewsWire
- 12 days ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 weeks ago - CytoDyn (CYDY) Secures $30 Million Funding Commitment from Yorkville - GuruFocus
- 4 weeks ago - CytoDyn (CYDY) Secures $30M Funding for Cancer Drug Development - GuruFocus
- 4 weeks ago - CytoDyn secures $30M equity funding commitment - Seeking Alpha
- 4 weeks ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire
- 6 weeks ago - Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - CytoDyn to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire